Be Biopharma is looking to hire highly motivated, experienced, and innovative thinkers to join our growing team of passionate researchers to leverage B cells as a novel class of cellular medicine. This is an exciting opportunity to be part of a foundational team and help build Be Bio!
Help to establish protocols around differentiation of primary immune cells, including extensive tissue culture work (maintenance, expansion, and banking)
Handling and analyzing workflows pertaining to cellular differentiation and profiling with downstream qRT-PCR, protein quantification, and other molecular readouts
Cloning of constructs to support cellular engineering efforts
Detailed record-keeping and protocol refinement as related to molecular and cellular assays
Facilitate efficient transfer of assays to CRO partners where applicable
Bachelor’s and 2+ years, or Master’s and 1+ years experience in a biopharmaceutical or biotechnology company
Experience in molecular biology techniques and cell culture (primary immune cells, B cells preferred)
Proven ability to establish and troubleshoot molecular biology assays
Excellent written and communication skills, ability to present scientific data
Ability to work collaboratively in a team setting and independently as needed
Clear demonstration of reproducible science with an attention to detail
Be Biopharma is developing a proprietary class of engineered B cell medicines to unleash the power of cell therapies beyond cell-cell contact-dependent killing (e.g., CAR-T cells). As the centerpiece of the body’s non-contact dependent humoral immune system, B cells offer a platform for cell therapy that can secrete large amounts of diverse molecular cargo in a physiologically-regulated manner. Based on discoveries by David Rawlings, MD (Chief of Immunology, Seattle Children’s and U Washington) and Richard James, PhD (Assoc Prof of Pediatrics, Seattle Children’s and U Washington), Be Biopharma is developing a pipeline of engineered B cell medicines that can restore lost signaling, regulate disease-causing pathways, and promote defense. The company will aim to demonstrate rapid proof-of-concept in genetically-defined monogenic disease, in parallel expanding to a broader set of applications across immune disease and oncology. Be Biopharma was founded in 2020 and is supported by a syndicate of leading biotech investors.